Evotec to hire across all sites with new €90m Novo investment

By Dani Bancroft

- Last updated on GMT

Evotec to hire across all sites with new €90m Novo investment

Related tags Novo nordisk Strategic management

Novo A/S is buying an additional €90m of shares in Evotec AG to accelerate and expand the German CRO’s outsourcing services.

Werner Lanthaler, CEO of Evotec,​ told Outsourcing-Pharma the €90m ($96m) investment will be “used for strategic growth of what we're doing, and to expand innovation projects within Evotec's R&D.”

This includes hiring of new staff and buying new equipment across all of Evotec’s sites, he added.

In particular, the firm’s 20 or so Cure X and Target X initiatives will be addressed, which span a range of indications from neurological to metabolic disease.

Lanthaler explained: “These initiatives are really academic translation. For example, we have a research partnership on neurological disease with Harvard, and another partnership with Yale.”

Novo A/S is the holding company in the Danish Novo Group, a family of independent companies owned by the Novo Nordisk Foundation.

Michael Shalmi, Managing Director of Large Investment at Novo commented “Supporting companies [like Evotec] provides more efficient solutions for the rapidly changing value chain in drug discovery and development.”

Multiple developments

Evotec has made several acquisitions and investments over the past six months, such as recently buying​ the UK-based ADMET services provider Cyprotex plc.

In January, the firm also launched​ a Toronto, Canada-based drug discovery company with MaRS Innovation, named Fibrocor Therapeutics LP.

Other deals the CRO made last month include with a German virtual biotech startup​ working on liver diseases, and a Japanese firm​ using ion channels for drug discovery.

“I think [Novo] went through Evotec’s business model, understood the combination of innovation and our highly innovative platform, and made a strategic move,” ​Lanthaler concluded.

With this investment, the Novo group now owns 8.9% of Evotec.


(Image: iStock/RomoloTavani)

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more